54 results match your criteria: "Center for Preclinical Research and Technology CEPT[Affiliation]"
Targeted deep resequencing of and in patients with diabetes and association of rare variants with leukotriene pathways.
Exp Ther Med
July 2016
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw 02-097, Poland.
Article Synopsis
- * Researchers sequenced 20 exons and their introns in 303 DNA samples from these patients to identify non-synonymous variants.
- * Despite finding 10 genetic variants in each gene, they concluded that these variants did not significantly differ between patients with low and high leukotriene concentrations, raising questions about the study's relevance to other populations beyond those with diabetes.
Common genetic variants in platelet surface receptors and its association with ischemic stroke.
Pharmacogenomics
June 2016
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
Ischemic stroke has been named one of the leading causes of death worldwide. Whereas numerous biological mechanisms and molecules were found to be associated with stroke, platelets are particularly contributive to its pathogenesis. Recent data indicate considerable variability in platelet phenotype which accounts for differences in platelet surface receptor function, count and reactivity.
View Article and Find Full Text PDFSerum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity but not to Genetic Polymorphisms within BDNF Encoding Gene in Patients with Type 2 Diabetes.
Med Sci Monit
January 2016
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
Background: The aim of this study was to investigate the association between serum concentrations of the brain-derived neurotrophic factor (BDNF), platelet reactivity and inflammatory markers, as well as its association with BDNF encoding gene variants in type 2 diabetic patients (T2DM) during acetylsalicylic acid (ASA) therapy.
Material/methods: This retrospective, open-label study enrolled 91 patients. Serum BDNF, genotype variants, hematological, biochemical, and inflammatory markers were measured.
Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid.
Platelets
June 2016
a Department of Experimental and Clinical Pharmacology , Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw , Poland.
Article Synopsis
- The study aimed to determine if rare genetic variations affect platelet reactivity in type 2 diabetes patients on acetylsalicylic acid (ASA) therapy.
- Researchers sequenced and analyzed specific genes connected to platelet function in 230 DNA samples from these patients and validated findings in a larger group of 384 samples.
- The results indicated that the accumulation of rare missense genetic variants significantly influenced platelet reactivity levels, suggesting these genetic factors may impact ASA treatment effectiveness in T2DM patients.